期刊文献+

慢性髓性白血病治疗新药asciminib药理作用及临床评价 被引量:1

Pharmacological effects and clinical evaluation of asciminib for chronic myeloid leukemia
原文传递
导出
摘要 慢性髓性白血病(chronic myeloid leukemia, CML)是一种起源于造血干细胞的恶性肿瘤,目前酪氨酸激酶抑制剂(tyrosine kinase inhibitors, TKIs)作为CML的一线治疗虽获得较好临床疗效,但也有部分患者出现TKIs治疗失败或不耐受,2021年10月29日,美国FDA批准BCR-ABL1酪氨酸激酶变构抑制剂asciminib上市,对≥2种TKIs耐药或不耐受的CML患者提供治疗方案,临床研究显示疗效佳且耐受性好。本文就其药理作用、临床评价、安全性及其用法用量等进行综述。 Chronic myeloid leukemia(CML) is a malignant tumor originating from hematopoietic stem cells. Currently, tyrosine kinase inhibitors(TKIs) have achieved good clinical efficacy as first-line treatment of CML. However, there are also some patients with TKIs treatment failure or intolerance. On October 29, 2021, FDA approved the marketing of asciminib, an allosteric inhibitor of BCR-ABL1 tyrosine kinase, to provide treatment for CML patients with ≥2 TKIs resistance or intolerance. Clinical studies have shown good efficacy and tolerability. This article reviews its pharmacological action, clinical evaluation, safety, usage and dosage.
作者 李春杏 刘丽艳 蔡金蕊 李妍 李佳忆 刘桦 LI Chun-xing;LIU Li-yan;CAI Jin-rui;LI Yan;LI Jia-yi;LIU Hua(Department of Pharmacy,Aerospace Center Hospital,Beijing 100049,China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2022年第22期2223-2226,共4页 Chinese Journal of New Drugs
关键词 慢性髓性白血病 asciminib 临床疗效 安全性 chronic myeloid leukemia asciminib clinical efficacy safety
  • 相关文献

参考文献3

二级参考文献61

  • 1黄河,蔡真,林茂芳,谢万灼,梁彬,李黎,何静松,罗依,郑伟燕,张洁,叶琇锦,胡晓蓉,陈水云,金爱云.非亲缘异基因骨髓移植治疗儿童白血病[J].中华儿科杂志,2004,42(11):835-839. 被引量:7
  • 2贺其图,时风桐,袁祖正.包头市白血病流行病学调查[J].内蒙古医学杂志,1993,13(2):3-5. 被引量:10
  • 3江倩,陈珊珊,江滨,江浩,丘镜滢,刘艳荣,张艳,秦亚溱,陆颖,黄晓军,陆道培.甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期100例追踪观察[J].中华血液学杂志,2006,27(11):721-726. 被引量:39
  • 4唐正贤 孙秋云 张金桃.上海市金山县11年白血病流行病学调查[J].中华血液学杂志,1994,15(8):430-430.
  • 5National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, V. 2. 2008. [ DB/OL]. (2007-10-25). http://www, nccn. org/profes- sionals/physician-gls/f-guidelines, asp#cml.
  • 6Druker BJ, Lee SJ. Chronic myelogenous leukemia//Cancer Prin- ciples and Practice of Oncology. 2007.
  • 7NCCN Clinical Practice Guidelines in oncology TM, Chronic My- elogenous Leukemia, V. 2. 2013. [ DB/OL]. http://www, nccn. org/professionals/physician-gls/f-guidelines, asp#cml.
  • 8Baccarani M, Pileri S, Steegmann JL, et al. Chronic myeloid leu- kemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann 0ncol,2012,23 Suppl 7 : vii72-vii77.
  • 9Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of the European LeukemiaNet. J Clin Oncol, 2009, 27:6041-6051.
  • 10World Health Organization Classification of Tumors. Pathology and Genetic of Tumors of Haematopoietic and Lymphoid Tissue. 2008.

共引文献94

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部